Congenital Heart Surgeons Society

CHSS Home CHSS Home Past & Future Meetings Past & Future Meetings

Back to 2026 Abstracts

A Single-center Experience With En-bloc Combined Heart+liver Transplantation: Analysis Of Ten Consecutive Patients, Including Three Undergoing Heart+liver+kidney Transplants
Mark S. Bleiweis, MD, Thiago Beduschi, MD, Werviston De Faria, MD, Michael S. Shillingford, MD, Giles J. Peek, MD, Jeffrey P. Jacobs, MD.
University of Florida, Gainesville, FL, USA.

OBJECTIVE: We review our single-center clinical experience over 5.1 years (August 3, 2020 through September 19, 2025, inclusive) with ten patients at our institution undergoing en-bloc combined heart+liver transplantation, three of whom underwent heart+liver+kidney transplantation.
METHODS: This analysis includes all patients undergoing en-bloc combined heart+liver transplantation at our institution.
RESULTS: Median age at transplant was 47.3 years (range=29.2-68.3). Congenital heart disease (CHD) was present in 7/10=70%: two had biventricular CHD and five had functionally univentricular circulation and Fontan failure. Median wait list time was 43.5 days (range=22-183). Three patients (3/10=30%) were supported with an intra-aortic balloon pump prior to transplantation, and two of these three patients were subsequently also supported with ECMO prior to transplantation. Two patients (2/10=20%) were supported with Impella prior to transplantation, and one patient (1/10=10%) was supported with a HeartMate 3 ventricular assist device for 7 years prior to heart+liver+kidney transplantation Median hospital length of stay was 147 days (range=51-308). Median posttransplant length of stay was of 32 days(range=2-55). One early death occurred 2 days after en-bloc combined heart+liver transplantation secondary to severe coagulopathy. One late death occurred 876 days after en-bloc combined heart+liver transplantation. Eight of 10 patients (80%) are alive today, with a median follow-up of 4.3 years (range=0.6 to 5.7 years)
CONCLUSIONS: En-bloc heart-liver transplantation is an effective treatment option for patients with combined heart and liver failure.
Back to 2026 Abstracts